NKTR
Nektar Therapeutics
NASDAQ: NKTR · HEALTHCARE · BIOTECHNOLOGY
$85.04
+2.21% today
Updated 2026-04-30
Market cap
$2.76B
P/E ratio
—
P/S ratio
50.03x
EPS (TTM)
$-9.73
Dividend yield
—
52W range
$8 – $109
Volume
1.1M
Nektar Therapeutics (NKTR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-297.10%
Operating margin
-87.50%
ROE
-217.90%
ROA
-28.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $217.72M | $-154.76M | 45.76% | -73.14% | -71.08% |
| 2007 | $273.03M | $-32.76M | 45.97% | -13.24% | -12.00% |
| 2008 | $90.19M | $-34.34M | 61.15% | -91.65% | -38.07% |
| 2009 | $71.93M | $-102.52M | 56.98% | -132.25% | -142.52% |
| 2010 | $159.04M | $-37.94M | 83.86% | -17.77% | -23.85% |
| 2011 | $71.48M | $-133.98M | 69.37% | -173.39% | -187.43% |
| 2012 | $81.19M | $-171.85M | 62.52% | -173.91% | -211.67% |
| 2013 | $148.92M | $-162.01M | 74.14% | -80.67% | -108.79% |
| 2014 | $200.71M | $-53.92M | 85.78% | -8.21% | -26.86% |
| 2015 | $230.78M | $-81.18M | 85.22% | -12.73% | -35.17% |
| 2016 | $165.44M | $-153.52M | 81.74% | -68.22% | -92.80% |
| 2017 | $307.71M | $-96.69M | 90.07% | -19.38% | -31.42% |
| 2018 | $1.19B | $681.31M | 97.95% | 57.65% | 57.09% |
| 2019 | $114.62M | $-440.67M | 81.35% | -383.92% | -384.47% |
| 2020 | $152.91M | $-444.44M | 87.26% | -248.45% | -290.65% |
| 2021 | $101.91M | $-523.84M | 75.57% | -437.76% | -514.03% |
| 2022 | $92.06M | $-368.20M | 76.50% | -260.97% | -399.98% |
| 2023 | $90.12M | $-276.06M | 59.34% | -152.49% | -306.31% |
| 2024 | $98.43M | $-118.96M | 68.82% | -106.88% | -120.86% |
| 2025 | $55.23M | $-164.08M | 100.00% | -236.77% | -297.07% |